AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18849173 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (5 mg)/Metformin (500 mg)
Number of subjects: 152
Study 17018657 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (8 weeks)
Number of subjects: 0
Study 15280527 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 55
Study 15280527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 16920315 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium (MnDPDP)
Number of subjects: 20
Study 16920315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferucarbotran
Number of subjects: 20
Study 10553859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg (D10)
Number of subjects: 150
Study 10553859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg (D5)
Number of subjects: 150
Study 10553859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.5 mg (D2.5)
Number of subjects: 150
Study 10553859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.25 mg (D1.25)
Number of subjects: 150
Study 10553859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 150
Study 8684648 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intercostal extrapleural block using bupivacaine 0.5%
Number of subjects: 0
Study 8684648 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine analgesia
Number of subjects: 0
Study 1884666 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety management
Number of subjects: 0
Study 1884666 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 0
Study 7121809 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 0
Study 7121809 — intervention group
Group type: COMPARATOR
Intervention: Meglumine-Ca-Metrizoate
Number of subjects: 0
Study 31796013 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic reminder and support calls
Number of subjects: 149
Study 31796013 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up care (Control)
Number of subjects: 149
Study 27612486 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement projects to improve communication between providers, workflow design, and chronic disease management.
Number of subjects: 34
Study 27612486 — intervention group
Group type: COMPARATOR
Intervention: Work conditions and provider outcomes
Number of subjects: 34
Study 26932142 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative duloxetine treatment
Number of subjects: 0
Study 26932142 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 0
Study 23592231 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioral therapy (cCBT)
Number of subjects: 0
Study 23592231 — intervention group
Group type: COMPARATOR
Intervention: Session email reminder
Number of subjects: 0
Study 23592231 — intervention group
Group type: COMPARATOR
Intervention: No-reminder condition
Number of subjects: 0
Study 21775122 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy intervention (Daidzein)
Number of subjects: 350
Study 21775122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 21775122 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 350
Study 19618811 — intervention group
Group type: EXPERIMENTAL
Intervention: Management-employee group received four one-hour interactive training sessions from a peer educator.
Number of subjects: 40
Study 19618811 — intervention group
Group type: COMPARATOR
Intervention: Management only group (control).
Number of subjects: 40
Study 19618811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received a report outlining deficiencies and prioritizing remediation.
Number of subjects: 40
Study 17626912 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued fume exposure
Number of subjects: 5724
Study 17626912 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued smoking
Number of subjects: 5724
Study 17626912 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway hyperresponsiveness
Number of subjects: 5724
Study 17626912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust exposure
Number of subjects: 5724
Study 17626912 — intervention group
Group type: EXPERIMENTAL
Intervention: Fume exposure in women
Number of subjects: 5724
Study 14699463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate antibiotic treatment
Number of subjects: 2634
Study 14699463 — intervention group
Group type: COMPARATOR
Intervention: Inadequate antibiotic treatment
Number of subjects: 2634
Study 11156542 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA‐1 cold light treatment
Number of subjects: 11
Study 11156542 — intervention group
Group type: COMPARATOR
Intervention: Placebo light treatment
Number of subjects: 11
Study 11156542 — intervention group
Group type: COMPARATOR
Intervention: UVA‐1 cold light treatment vs Placebo
Number of subjects: 11
Study 9683005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg i.v.
Number of subjects: 18
Study 7719089 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoyu pian (XYP)
Number of subjects: 137
Study 7719089 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C and P and/or adrenosem (Control)
Number of subjects: 137
Study 31122618 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium scores (CACS) from non-electrocardiogram-gated chest computed tomography (CT)
Number of subjects: 953
Study 28569454 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin + Clavulanic acid (2 g/day for 6 days)
Number of subjects: 111
Study 28569454 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic + Probiotic (Bifidobacterium longum + lactoferrin)
Number of subjects: 111
Study 28569454 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic therapy (Control group)
Number of subjects: 111
Study 25358635 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie training
Number of subjects: 52
Study 25358635 — intervention group
Group type: COMPARATOR
Intervention: Classic kinetic exercises (Control)
Number of subjects: 52
Study 23589506 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise and health education programme
Number of subjects: 67
Study 23589506 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 22098700 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise group (5 times per week for 8 weeks)
Number of subjects: 40
Study 22098700 — intervention group
Group type: COMPARATOR
Intervention: Non‐treated group (maintain current lifestyle)
Number of subjects: 40
Study 18205033 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 31
Study 18205033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16536777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal neobladder (Group A)
Number of subjects: 60
Study 16536777 — intervention group
Group type: COMPARATOR
Intervention: Ileocaecal bladder substitution (Group B)
Number of subjects: 60
Study 12555926 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 42
Study 12555926 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 42
Study 10996387 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxiphylline
Number of subjects: 19
Study 10996387 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 19
Study 9349846 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-yearly mebendazole (500 mg)
Number of subjects: 1000
Study 9349846 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-yearly mebendazole (500 mg)
Number of subjects: 1000
Study 9349846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no deworming)
Number of subjects: 1000
Study 9349846 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming (general)
Number of subjects: 1000
Study 8416325 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 3297
Study 8416325 — intervention group
Group type: COMPARATOR
Intervention: Control (no beta-blocker therapy)
Number of subjects: 3297
Study 3709031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetamolol (46 +/- 21 mg/day)
Number of subjects: 12
Study 3709031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetamolol
Number of subjects: 12
Study 3709031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29393233 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 200 IU/day
Number of subjects: 80
Study 29393233 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 800 IU/day
Number of subjects: 80
Study 29393233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29393233 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen or asthma medications
Number of subjects: 80
Study 25790770 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5-mm diameter implant (test)
Number of subjects: 57
Study 25790770 — intervention group
Group type: COMPARATOR
Intervention: 3.75-mm diameter implant (control)
Number of subjects: 57
Study 25790770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both implants
Number of subjects: 57
Study 24037900 — intervention group
Group type: COMPARATOR
Intervention: IPL 0 J/cm²
Number of subjects: 21
Study 24037900 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL 7 J/cm²
Number of subjects: 21
Study 24037900 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL 8 J/cm²
Number of subjects: 21
Study 24037900 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL 10 J/cm²
Number of subjects: 21
Study 24037900 — intervention group
Group type: EXPERIMENTAL
Intervention: UVR exposure (0 or 8 exposures of 2-4 SED)
Number of subjects: 21
Study 24037900 — intervention group
Group type: EXPERIMENTAL
Intervention: All IPL doses
Number of subjects: 21
Study 23276521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant 5‐fluorouracil (5‐FU)‐based chemotherapy
Number of subjects: 716
Study 23276521 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 716
Study 19466423 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 39
Study 19466423 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study 18467085 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 23
Study 18467085 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient care
Number of subjects: 23
Study 15983954 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 155
Study 15983954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 15983954 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (without diabetes)
Number of subjects: 155
Study 15983954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without diabetes)
Number of subjects: 155
Study 15983954 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (postoperative cardiothoracic patients)
Number of subjects: 155
Study 15983954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (postoperative cardiothoracic patients)
Number of subjects: 155
Study 13678932 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 13678932 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 10566571 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d for 12 weeks (n = 194)
Number of subjects: 387
Study 10566571 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/d for 12 weeks (n = 193)
Number of subjects: 387
Study 10566571 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d for 12 weeks
Number of subjects: 387
Study 10566571 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/d for 12 weeks
Number of subjects: 387
Study 9084544 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 160
Study 9084544 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 160
Study 9084544 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 40 mg
Number of subjects: 160
Study 9084544 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study 1816244 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial prophylactic exchange transfusion (continuous flow erythrocytapheresis)
Number of subjects: 131
Study 1816244 — intervention group
Group type: COMPARATOR
Intervention: Blood only when serious complications developed (control group)
Number of subjects: 131
Study 6978111 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine at 5.0 micrograms/kg/min
Number of subjects: 20
Study 6978111 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine at 5.0 micrograms/kg/min
Number of subjects: 20
Study 6978111 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine at 7.5 micrograms/kg/min
Number of subjects: 20
Study 6978111 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine from 5.0 to 7.5 micrograms/kg/min
Number of subjects: 20
Study 30701815 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal suppositories containing IFN‐α2b (1 million IU) and antioxidants (alpha‐tocopherol acetate and ascorbic acid) twice a day for 5 days
Number of subjects: 90
Study 30701815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal gel formulation containing IFN‐α2b (36 000 IU/1 g) and antioxidants 3 times a day in addition to rectal suppositories
Number of subjects: 90
Study 30701815 — intervention group
Group type: COMPARATOR
Intervention: Umifenovir (reference drug) at a dose of 200 mg 4 times a day for 5 days
Number of subjects: 90
Study 30701815 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rectal and topical dosage forms of IFN‐α2b with antioxidants
Number of subjects: 90
Study 26645282 — intervention group
Group type: COMPARATOR
Intervention: Supervised training (SUP) - 2/week supervised training, 1/week unsupervised training
Number of subjects: 66
Study 26645282 — intervention group
Group type: COMPARATOR
Intervention: Unsupservised training (UNSUP) - 3/week unsupervised training
Number of subjects: 66
Study 26645282 — intervention group
Group type: COMPARATOR
Intervention: Passive control group (CON)
Number of subjects: 66
Study 23506657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 357
Study 23506657 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 357
Study 23506657 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 357
Study 22898573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit™ with physiotherapy session
Number of subjects: 50
Study 22898573 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy session with lower extremity strengthening and balance training exercises
Number of subjects: 50
Study 20505654 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids + Cyclophosphamide
Number of subjects: 54
Study 20505654 — intervention group
Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 54
Study 18284895 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to a befriender facilitator (BF)
Number of subjects: 236
Study 18284895 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 236
Study 16126373 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotiapine (40 mg)
Number of subjects: 58
Study 16126373 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (100 mg)
Number of subjects: 58
Study 14728113 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 37
Study 14728113 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SSRIs with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 37
Study 10997885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) therapy in PV patients
Number of subjects: 37
Study 10997885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) therapy in ET patients
Number of subjects: 37
Study 10997885 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy therapy in PV patients
Number of subjects: 37
Study 10997885 — intervention group
Group type: COMPARATOR
Intervention: Untreated ET patients
Number of subjects: 37
Study 10997885 — intervention group
Group type: COMPARATOR
Intervention: Combined groups of PV and ET without myelosuppressive treatment
Number of subjects: 37
Study 10997885 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cells in peripheral blood
Number of subjects: 37
Study 8987041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 75
Study 8987041 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 75
Study 8987041 — intervention group
Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 75
Study 1479457 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous negative pressure
Number of subjects: 30
Study 1479457 — intervention group
Group type: COMPARATOR
Intervention: Positive end-expiratory pressure
Number of subjects: 30
Study 1479457 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 30
Study 3830481 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 78
Study 3830481 — intervention group
Group type: COMPARATOR
Intervention: Control (non-adenoidectomized children)
Number of subjects: 78
Study 31533799 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (including cognitive-behavioral therapy, care management, and psychotropic medication consultation)
Number of subjects: 200
Study 31533799 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 200
Study 30365589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 1640
Study 30365589 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1640
Study 26797940 — intervention group
Group type: EXPERIMENTAL
Intervention: JASPER parent‐mediated intervention
Number of subjects: 85
Study 26797940 — intervention group
Group type: COMPARATOR
Intervention: Parent psychoeducation intervention
Number of subjects: 85
Study 24447110 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% glycolic acid (GA) peels applied on half of the face, performed five times at 2-week intervals
Number of subjects: 26
Study 24447110 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied on the other half of the face
Number of subjects: 26
Study 22130792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg/d (group A)
Number of subjects: 36
Study 22130792 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium perchlorate 500 mg twice daily (group B)
Number of subjects: 36
Study 22130792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus perchlorate (group C)
Number of subjects: 36
Study 22130792 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 36
Study 20639801 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomically shaped permanent expander implant McGhan Style 150
Number of subjects: 36
Study 20639801 — intervention group
Group type: COMPARATOR
Intervention: Round permanent expander implant Siltex Becker 25
Number of subjects: 36
Study 17931949 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postoperative irradiation (60 Gy delivered over 6 weeks)
Number of subjects: 1005
Study 15855572 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 336
Study 15855572 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 336
Study 15855572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 10883415 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg) administered orally during the follicular phase
Number of subjects: 11
Study 10883415 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg) administered orally during the ovulatory phase
Number of subjects: 11
Study 10883415 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg) administered orally during the luteal phase
Number of subjects: 11
Study 10883415 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the follicular phase
Number of subjects: 11
Study 10883415 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the ovulatory phase
Number of subjects: 11
Study 10883415 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (0.5 mg/kg) administered as an i.v. bolus during the luteal phase
Number of subjects: 11
Study 9187068 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (10 microg per kilogram of body weight per day subcutaneously)
Number of subjects: 164
Study 1586602 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low dose infusion of recombinant interleukin-2 (rIL-2) at doses of 0.18 x 10(6) IU, 0.6 x 10(6) IU, 1.8 x 10(6) IU, 3 x 10(6) IU, 6 x 10(6) IU, and 9 x 10(6) IU per m2 per 24 h.
Number of subjects: 22
Study 1586602 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low dose infusion of recombinant interleukin-2 (rIL-2) at a dose of 1.8 x 10(6) IU m-2 24 h-1.
Number of subjects: 22
Study 31810484 — intervention group
Group type: EXPERIMENTAL
Intervention: PJIRSTR
Number of subjects: 300
Study 31810484 — intervention group
Group type: EXPERIMENTAL
Intervention: PJIRDTR
Number of subjects: 300
Study 31810484 — intervention group
Group type: COMPARATOR
Intervention: TGRY
Number of subjects: 300
Study 31810484 — intervention group
Group type: EXPERIMENTAL
Intervention: PJIRSTR and PJIRDTR
Number of subjects: 300
Study 31810484 — intervention group
Group type: EXPERIMENTAL
Intervention: PJIRSTR, PJIRDTR, TGRY
Number of subjects: 300
Study 29587851 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 185
Study 29587851 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by Adalimumab
Number of subjects: 185
Study 29587851 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 185
Study 27756277 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump Start intervention
Number of subjects: 0